Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals.

IF 5.9 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Hepatology International Pub Date : 2024-10-01 Epub Date: 2024-08-08 DOI:10.1007/s12072-024-10716-z
Matheus Souza, Ivanna Diaz, Lubna Al-Sharif
{"title":"Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals.","authors":"Matheus Souza, Ivanna Diaz, Lubna Al-Sharif","doi":"10.1007/s12072-024-10716-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Non-alcoholic fatty liver disease (NAFLD) is present in lean people. However, the magnitude of the prognostic hepatic and cardiovascular risk in these patients compared to non-lean counterparts remains unclear. We aimed to investigate this topic, and to explore whether these risks change based on factors related to NAFLD severity.</p><p><strong>Methods: </strong>PubMed and Embase databases were searched for cohort studies (published through April 2024) that evaluated liver and cardiovascular (CV) outcomes in lean and non-lean individuals with NAFLD and reported unadjusted or adjusted data. We pooled risk ratios (RRs) or hazard ratios (HRs) using a random-effects modeling and performed subgroup and meta-regressions analyses.</p><p><strong>Results: </strong>We identified 22 studies with over 1 million NAFLD patients (13.0% were lean). Lean NAFLD showed a similar risk of liver-related events in unadjusted analysis (RR 1.08, 95% CI 0.79-1.49, I<sup>2</sup> = 31%), but a higher risk in adjusted analysis (HR 1.66, 95% CI 1.17-2.36, I<sup>2</sup> = 83%) compared to non-lean NAFLD. Lean NAFLD had a higher risk of liver-related mortality (RR 2.22, 95% CI 1.57-3.15, I<sup>2</sup> = 0%; HR 2.26, 95% CI 1.14-4.51, I<sup>2</sup> = 0%). For CV outcomes, lean NAFLD had a lower risk of any cardiovascular disease in unadjusted analysis (RR = 0.82, 95% CI 0.70-0.95, I<sup>2</sup> = 88%), but similar risk in adjusted analysis (HR 0.89, 95% CI 0.77-1.02, I<sup>2</sup> = 78%), and similar risk of cardiovascular mortality (RR 1.09, 95% CI 0.71-1.66, I<sup>2</sup> = 85%; HR 1.26, 95% CI 0.89-1.78, I<sup>2</sup> = 46%) compared to non-lean NAFLD.</p><p><strong>Conclusions: </strong>Lean NAFLD patients have worse liver outcomes, but similar CV outcomes compared to non-lean NAFLD patients, highlighting the importance of monitoring both groups closely.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1396-1415"},"PeriodicalIF":5.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12072-024-10716-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims: Non-alcoholic fatty liver disease (NAFLD) is present in lean people. However, the magnitude of the prognostic hepatic and cardiovascular risk in these patients compared to non-lean counterparts remains unclear. We aimed to investigate this topic, and to explore whether these risks change based on factors related to NAFLD severity.

Methods: PubMed and Embase databases were searched for cohort studies (published through April 2024) that evaluated liver and cardiovascular (CV) outcomes in lean and non-lean individuals with NAFLD and reported unadjusted or adjusted data. We pooled risk ratios (RRs) or hazard ratios (HRs) using a random-effects modeling and performed subgroup and meta-regressions analyses.

Results: We identified 22 studies with over 1 million NAFLD patients (13.0% were lean). Lean NAFLD showed a similar risk of liver-related events in unadjusted analysis (RR 1.08, 95% CI 0.79-1.49, I2 = 31%), but a higher risk in adjusted analysis (HR 1.66, 95% CI 1.17-2.36, I2 = 83%) compared to non-lean NAFLD. Lean NAFLD had a higher risk of liver-related mortality (RR 2.22, 95% CI 1.57-3.15, I2 = 0%; HR 2.26, 95% CI 1.14-4.51, I2 = 0%). For CV outcomes, lean NAFLD had a lower risk of any cardiovascular disease in unadjusted analysis (RR = 0.82, 95% CI 0.70-0.95, I2 = 88%), but similar risk in adjusted analysis (HR 0.89, 95% CI 0.77-1.02, I2 = 78%), and similar risk of cardiovascular mortality (RR 1.09, 95% CI 0.71-1.66, I2 = 85%; HR 1.26, 95% CI 0.89-1.78, I2 = 46%) compared to non-lean NAFLD.

Conclusions: Lean NAFLD patients have worse liver outcomes, but similar CV outcomes compared to non-lean NAFLD patients, highlighting the importance of monitoring both groups closely.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
瘦型非酒精性脂肪肝的肝脏和心血管后果:对约 100 万人进行的最新系统回顾和荟萃分析。
背景和目的:非酒精性脂肪肝(NAFLD)存在于体型偏瘦的人群中。然而,与非瘦人相比,这些患者的肝脏和心血管预后风险的大小仍不清楚。我们旨在研究这一课题,并探讨这些风险是否会因非酒精性脂肪肝严重程度的相关因素而发生变化:我们在 PubMed 和 Embase 数据库中检索了对患有非酒精性脂肪肝的瘦弱和非瘦弱患者的肝脏和心血管 (CV) 结果进行评估的队列研究(发表至 2024 年 4 月),并报告了未调整或调整后的数据。我们采用随机效应模型对风险比(RRs)或危险比(HRs)进行了汇总,并进行了亚组和元回归分析:我们确定了 22 项研究,涉及超过 100 万名非酒精性脂肪肝患者(13.0% 为瘦型)。在未调整分析中,瘦型非酒精性脂肪肝发生肝脏相关事件的风险相似(RR 1.08,95% CI 0.79-1.49,I2 = 31%),但在调整分析中,与非瘦型非酒精性脂肪肝相比,瘦型非酒精性脂肪肝发生肝脏相关事件的风险更高(HR 1.66,95% CI 1.17-2.36,I2 = 83%)。瘦型非酒精性脂肪肝的肝脏相关死亡风险更高(RR 2.22,95% CI 1.57-3.15,I2 = 0%;HR 2.26,95% CI 1.14-4.51,I2 = 0%)。对于心血管疾病的结局,在未调整分析中,非酒精性脂肪肝瘦患者罹患任何心血管疾病的风险较低(RR = 0.82,95% CI 0.70-0.95,I2 = 88%),但在调整分析中风险相似(HR 0.89,95% CI 0.77-1.02,I2 = 78%),与非瘦型非酒精性脂肪肝相比,心血管死亡风险相似(RR 1.09,95% CI 0.71-1.66,I2 = 85%;HR 1.26,95% CI 0.89-1.78,I2 = 46%):瘦型非酒精性脂肪肝患者的肝脏预后较差,但与非瘦型非酒精性脂肪肝患者的心血管预后相似,这凸显了密切监测这两类患者的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hepatology International
Hepatology International 医学-胃肠肝病学
CiteScore
10.90
自引率
3.00%
发文量
167
审稿时长
6-12 weeks
期刊介绍: Hepatology International is the official journal of the Asian Pacific Association for the Study of the Liver (APASL). This is a peer-reviewed journal featuring articles written by clinicians, clinical researchers and basic scientists is dedicated to research and patient care issues in hepatology. This journal will focus mainly on new and emerging technologies, cutting-edge science and advances in liver and biliary disorders. Types of articles published: -Original Research Articles related to clinical care and basic research -Review Articles -Consensus guidelines for diagnosis and treatment -Clinical cases, images -Selected Author Summaries -Video Submissions
期刊最新文献
Clinical characteristics and managements of congenital hepatic hemangioma: a cohort study of 211 cases. AARC score and urine NGAL predict terlipressin non-response and mortality in patients with acute-on-chronic liver failure. Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study. Global, regional, and national epidemiology of hepatoblastoma in children from 1990 to 2021: a trend analysis. Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1